BIOA BIOAGE LABS INC.

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil,

IR: Dov Goldstein,

Partnering:

Web:



EN
20/02/2025

Underlying

BIOABIOAGE LABS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOAGE LABS INC.

 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides...

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) --  BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Ob...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company devel...

June 21, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Expands Drug Discovery Platform with Data from Leading Eur...

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targetin...

June 17, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-...

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its a...

June 3, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs completes IND-enabling studies for BGE-102, a potent, oral...

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinic...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch